Comparative Pharmacology
Head-to-head clinical analysis: LIDOCATON versus SEPTOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCATON versus SEPTOCAINE.
LIDOCATON vs SEPTOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, inhibiting the inward sodium current, thereby stabilizing cardiac membranes, decreasing automaticity, and increasing the fibrillation threshold. It also acts as a local anesthetic by reversibly blocking nerve impulse propagation.
Articaine is a local anesthetic of the amide type that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse conduction.
Lidocaine: Initial IV bolus 1-1.5 mg/kg, then IV infusion 1-4 mg/min. Adjust for arrhythmia suppression.
SEPTOCAINE (articaine HCl 4% with epinephrine 1:100,000 or 1:200,000) dental infiltration or nerve block: 0.5–1.7 mL (20–68 mg articaine) per injection site; maximum adult dose: 7 mg/kg (up to 500 mg total).
None Documented
None Documented
Terminal half-life 1.5–2 hours (adults); prolonged in heart failure (up to 4–6 hours) or hepatic impairment (up to 8 hours).
Terminal elimination half-life in adults is 2-4 hours. In neonates, it may be prolonged to 8-12 hours due to immature hepatic function.
Renal: ~90% as metabolites (major metabolite 4-hydroxyxylidine) and ~10% unchanged. Biliary/fecal: <5%.
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic